Treace Medical Concepts, Inc. (NASDAQ: TMCI), shares strengthened Friday. The medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the first quarter ended March 31, 2026.
Generated revenue of $47.2 million in first quarter 2026 compared to $52.6 million in the same period in 2025. Reported first-quarter 2026 net loss of $(18.0) million and adjusted EBITDA of $(5.5) million in the first quarter 2026.
Cash, cash equivalents, and marketable securities totaled $51.9 million as of March 31, 2026, representing an increase of $3.5 million from the Company’s balance of $48.4 million as of December 31, 2025, and compares to an increase of approximately $0.4 million in the first quarter of 2025.
Initiated limited market release of SuperBite™ Compression Screw System with successful first commercial cases.
Broadened global patent portfolio surpassing 130 granted patents in addition to over 200 pending patent applications.
Said CEO John Treace, “We are encouraged by the growing demand for our comprehensive portfolio of best-in-class bunion and midfoot correction systems, including our new products, which expand our addressable procedure opportunities across our growing surgeon base.”
TMCI shares took on five cents, or 2.6%, to $1.97.
